ClinConnect ClinConnect Logo
Search / Trial NCT06528821

AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS

Launched by POWERFUL MEDICAL · Jul 26, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Acute Coronary Syndrome Ecg Artificial Intelligence Occlusion Myocardial Infarction Myocardial Infarction (Mi)

ClinConnect Summary

This clinical trial, called AI ECG TIMI, is studying how an advanced artificial intelligence (AI) model can help doctors identify problems with blood flow in the heart of patients experiencing acute coronary syndrome (ACS). ACS includes serious conditions like heart attacks (STEMI and NSTEMI), where blood supply to the heart is suddenly reduced or blocked. The goal is to see if the AI can analyze electrocardiograms (ECGs)—a test that measures the electrical activity of the heart—and predict issues in blood flow just before a procedure called invasive coronary angiography, which doctors use to look at the heart's blood vessels.

To participate in this trial, patients need to be at least 18 years old and must be experiencing symptoms of ACS that require emergency medical attention, leading to an invasive coronary angiography. However, those who are having non-emergency procedures or have chronic heart problems won't be included. If eligible, participants can expect to have a standard ECG done shortly before their angiography, allowing researchers to gather important information about how well the AI can work in real-life situations. This study is currently recruiting participants from various locations, aiming to improve how doctors diagnose and treat heart conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with acute coronary syndromes undergoing invasive coronary angiography as clinically indicated.
  • Availability of a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access).
  • Age ≥18 years.
  • Exclusion Criteria:
  • Individuals presenting for a non-emergent (elective) cardiac catheterization.
  • Individuals presenting with chronic coronary syndrome (CCS) or stable angina symptoms.
  • Individuals without symptoms suspicious for acute coronary syndromes.
  • Individuals with contraindications for cardiac catheterization.

About Powerful Medical

Powerful Medical is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on transformative therapies and cutting-edge technologies, the organization collaborates with healthcare professionals, institutions, and patients to conduct robust clinical trials that address unmet medical needs. Committed to ethical practices and regulatory compliance, Powerful Medical employs a multidisciplinary approach to ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and improve quality of life.

Locations

Aalst, , Belgium

Graz, , Austria

Brugge, , Belgium

Hasselt, , Belgium

Bratislava, , Slovakia

Bruck An Der Mur, , Austria

Graz, , Austria

Chieti, , Italy

Rome, , Italy

Rome, , Italy

Patients applied

0 patients applied

Trial Officials

Robert Herman, MD, PhD

Principal Investigator

Powerful Medical

Emanuele Barbato, MD, PhD

Study Chair

University of Roma La Sapienza

Jozef Bartunek, MD, PhD

Study Chair

Azorg Hospital, Aalst

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported